Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points

被引：7
|
作者：
Law, Ernest [1 ]
Gavanji, Roya [2 ]
Walsh, Sarah [3 ]
Haltner, Anja [3 ]
McTavish, Rebecca [2 ]
Cameron, Chris [3 ]
机构：
[1] Pfizer, New York, NY 10017 USA
[2] EVERSANA, Burlington, ON L7N 3H8, Canada
[3] EVERSANA, Sydney, NS B1P 1C6, Canada
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 11卷 / 02期
关键词：
abemaciclib; advanced breast cancer; health-related quality of life; HER2-negative; hormone receptor-positive; indirect treatment comparison; matching-adjusted indirect comparison; palbociclib; patient-reported outcomes; quality of life; QUALITY-OF-LIFE; MONARCH; 2; ABEMACICLIB; PLUS FULVESTRANT; COMBINATION; GUIDELINES; OUTCOMES; WOMEN; CARE;
D O I：
10.2217/cer-2021-0221
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: To assess the relative impact of palbociclib plus fulvestrant (PAL + FUL) and abemaciclib plus fulvestrant (ABEM + FUL) on patient-reported outcomes in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Patients & methods: Anchored matching-adjusted indirect comparisons were conducted using individual patient data from PALOMA-3 (PAL + FUL) and summary-level data from MONARCH-2 (ABEM + FUL). Outcomes included the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30) and its breast cancer-specific module (QLQ-BR23). Results: Significantly different changes from baseline favoring PAL + FUL compared with ABEM + FUL were observed in global quality of life (6.95 [95% CI: 2.19-11.71]; p = 0.004) and several functional/symptom scales, including emotional functioning, nausea/vomiting, appetite loss, diarrhea and systemic therapy side effects. Conclusion: PAL + FUL was associated with more favorable patient-reported outcomes than ABEM + FUL in patients with HR+/HER2- advanced breast cancer.
引用
收藏
页码：109 / 120
页数：12
相关论文
共 50 条
  • [21] Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2-advanced breast cancer
    Hao, Chunfang
    Bai, Xuedong
    Zhang, Jie
    Meng, Wenjing
    Tong, Zhongsheng
    THORACIC CANCER, 2023, 14 (01) : 68 - 72
  • [22] MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer who progressed on endocrine therapy
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier B.
    Burdaeva, Olga Nikolaevna
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han A.
    Grischke, Eva-Maria
    Frenzel, Martin
    Lin, Yong
    Barriga, Susana
    Smith, Ian C.
    Bourayou, Nawel
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] COST-EFFECTIVENESS OF PALBOCICLIB PLUS LETROZOLE IN THE TREATMENT OF HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN ECUADOR
    Cabezas, M.
    Freire, V
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [24] Therapy of HR+/HER2-advanced or metastatic Breast Cancer Palbociclib: Importance of Data from Everyday Care for Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [25] Palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer patients: Interim results of the PERFORM study
    Radosa, J. C.
    Fietz, T.
    Wilke, J.
    Decker, T.
    Petersen, V.
    Deryal, M.
    Knoblich, J.
    Losem, C.
    Rhein, U.
    Schoettker, B.
    Wrobel, D.
    Pfeiler, G.
    Zanucco, E.
    Buncke, J.
    Woerner, S.
    Gratzke, K.
    Adams, A.
    Glastetter, E.
    Bartsch, R.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S353 - S354
  • [26] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Mitova, R.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [27] Abemaciclib for the treatment of HR+/HER2- breast cancer
    Exman, Pedro
    Tolaney, Sara M.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
  • [28] A randomized trial of abemaciclib in combination with fulvestrant compared to chemotherapy in women with HR+, HER2-advanced breast cancer with visceral metastases
    Kaufman, Peter
    Glaspy, John
    Zhang, Wei
    Koustenis, Andrew
    Chen, Yanyun
    Brufsky, Adam
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Management of abemaciclib-associated adverse events in patients with HR+/HER2-advanced breast cancer: analysis of the MONARCH trials
    Rugo, H. S.
    Huober, J.
    Llombart-Cussac, A.
    Toi, M.
    Tolaney, S.
    Andre, V.
    Barriga, S.
    Forrester, T.
    Sledge, Jr G. W.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 289 - 289
  • [30] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Huang, C-S.
    Toi, M.
    Im, Y-H.
    Iwata, H.
    Sohn, J.
    Wang, H-C.
    Masuda, N.
    Im, S-A.
    Lu, Y.
    Haddad, N.
    Sakaguchi, S.
    Hurt, K.
    Neven, P.
    Llombart-Cussac, A.
    Sledge, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1259
12345